SEC For	m 4																	
FORM 4 UNITED S) STAT	TATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL													
Check transac contrac the pur securit to satis	n 16. Form 4 or ions may contin tion 1(b). this box to india tion was made st, instruction or chase or sale c ies of the issue fy the affirmativ ons of Rule 10b	use. See cate that a pursuant to a written plan for of equity r that is intended we defense	STAT		pursua	F CHAN nt to Section ction 30(h) o	16(a) of the Se	ecurit	ies Exchanç	ge Act of 19		HIP	OMB Estim	Number	r: erage burde	3235-0287	
1. Name and Address of Reporting Person* Adams Catherine Owen					2. Issuer Name and Ticker or Trading Symbol <u>ACADIA PHARMACEUTICALS INC</u> [ACAD]								Officer (give title Oth			n(s) to Issu 10% O Other (below)	wner	
(Last)(First)(Middle)C/O ACADIA PHARMACEUTICALS INC.12830 EL CAMINO REAL, SUITE 400					3. Date of Earliest Transaction (Month/Day/Year) 09/23/2024								Chief Executive Officer					
(Street) SAN DII (City)	EGO C (S	92130 (Zip)										 idividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person 						
1. Title of Security (Instr. 3) 2. Trans Date				2. Transac	action 2A. Deemed Execution Date,			3. Transa Code (8)	iction Instr.	r. (A) ==		d (A) or 3, 4 and 5	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		Form: Direct I (D) or Indirect I (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Code V Amount (A) Or (D) Price Iransaction(s) (Instr. 3 and 4) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) Image: Code (Instr. 3 and 4)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	4. Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisab Expiration Date (Month/Day/Year)		sable and e			ount 8. Price of Derivative Security		er of ve es ally lg d tion(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisa	ble	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)				
Stock Option (Right to Buy)	\$16.29	09/23/2024		А		353,261 ⁽¹⁾		(2)		09/22/2034	Common Stock	353,261	\$0	353,2	261	D		
Evolopatio	n of Poenone	06'																

Explanation of Responses:

1. The Stock Option has been granted pursuant to the Issuer's 2024 Inducement Plan as a material inducement to the reporting person's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

2. 25% of the shares subject to the Stock Option will vest and become exercisable on September 23, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

/s/ Jennifer J. Rhodes, Attorney-09/25/2024 in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.